UNLABELLED: New rotavirus vaccines show promise to reduce the burden of severe diarrhea among children in developing countries. We present an age-specific dynamic rotavirus model to assess the effect of rotavirus vaccination in Kyrgyzstan, a country in Central Asia that is eligible for funds from the GAVI Alliance. A routine rotavirus vaccination program at 95% coverage and 54% effectiveness against severe infection is estimated to lead to a 56% reduction in rotavirus-associated deaths and a 50% reduction in hospital admissions, while outpatient visits and homecare episodes would decrease by 52% compared to baseline levels after 5 years of intervention. A 10% reduction in vaccine efficacy due to incomplete 3-dose regimen is estimated to increase the numbers of severe cases by 6-8%. Herd immunity was found to account for 1% or less of averted cases of severe gastroenteritis, while an extra 7-8% of all rotavirus infections would be avoided due to reduced transmission. CONCLUSION: Rotavirus vaccines would reduce the burden of rotavirus disease substantially, but the results are sensitive to delay in age-appropriate vaccination.
UNLABELLED: New rotavirus vaccines show promise to reduce the burden of severe diarrhea among children in developing countries. We present an age-specific dynamic rotavirus model to assess the effect of rotavirus vaccination in Kyrgyzstan, a country in Central Asia that is eligible for funds from the GAVI Alliance. A routine rotavirus vaccination program at 95% coverage and 54% effectiveness against severe infection is estimated to lead to a 56% reduction in rotavirus-associated deaths and a 50% reduction in hospital admissions, while outpatient visits and homecare episodes would decrease by 52% compared to baseline levels after 5 years of intervention. A 10% reduction in vaccine efficacy due to incomplete 3-dose regimen is estimated to increase the numbers of severe cases by 6-8%. Herd immunity was found to account for 1% or less of averted cases of severe gastroenteritis, while an extra 7-8% of all rotavirus infections would be avoided due to reduced transmission. CONCLUSION: Rotavirus vaccines would reduce the burden of rotavirus disease substantially, but the results are sensitive to delay in age-appropriate vaccination.
Authors: Virginia E Pitzer; Manish M Patel; Ben A Lopman; Cécile Viboud; Umesh D Parashar; Bryan T Grenfell Journal: Proc Natl Acad Sci U S A Date: 2011-11-14 Impact factor: 11.205
Authors: Emily R Smith; Emily E Rowlinson; Volga Iniguez; Kizee A Etienne; Rosario Rivera; Nataniel Mamani; Rick Rheingans; Maritza Patzi; Percy Halkyer; Juan S Leon Journal: Vaccine Date: 2011-09-02 Impact factor: 3.641
Authors: Alicia N M Kraay; Andrew F Brouwer; Nan Lin; Philip A Collender; Justin V Remais; Joseph N S Eisenberg Journal: Proc Natl Acad Sci U S A Date: 2018-03-01 Impact factor: 11.205
Authors: Virginia E Pitzer; Aisleen Bennett; Naor Bar-Zeev; Khuzwayo C Jere; Benjamin A Lopman; Joseph A Lewnard; Umesh D Parashar; Nigel A Cunliffe Journal: Sci Transl Med Date: 2019-08-14 Impact factor: 17.956
Authors: Alicia N M Kraay; James Trostle; Andrew F Brouwer; William Cevallos; Joseph N S Eisenberg Journal: Epidemiology Date: 2018-01 Impact factor: 4.822
Authors: Virginia E Pitzer; Cécile Viboud; Ben A Lopman; Manish M Patel; Umesh D Parashar; Bryan T Grenfell Journal: J R Soc Interface Date: 2011-04-20 Impact factor: 4.118
Authors: Virginia E Pitzer; Katherine E Atkins; Birgitte Freiesleben de Blasio; Thierry Van Effelterre; Christina J Atchison; John P Harris; Eunha Shim; Alison P Galvani; W John Edmunds; Cécile Viboud; Manish M Patel; Bryan T Grenfell; Umesh D Parashar; Ben A Lopman Journal: PLoS One Date: 2012-08-13 Impact factor: 3.240